Get started
Author

Margaret M. Showel

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide
2015 · Shannon R. McCurdy, Jennifer A. Kanakry, et al. · Blood · 303
Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults
2015 · Yvette L. Kasamon, Javier Bolaños-Meade, et al. · Journal of Clinical Oncology · 239
Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS
2014 · Christopher G. Kanakry, Hua-Ling Tsai, et al. · Blood · 203
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide
2016 · Shannon R. McCurdy, Yvette L. Kasamon, et al. · Haematologica · 194
PDF
Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes
1996 · Vilasini Shetty, Suneel Mundle, et al. · Leukemia Research · 177
Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias
2012 · Judith E. Karp, Brian M. Thomas, et al. · Clinical Cancer Research · 117
Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide
2017 · Shannon R. McCurdy, Christopher G. Kanakry, et al. · Transplantation and Cellular Therapy · 79
PDF
Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults
2020 · Heather J. Symons, Marianna Zahurak, et al. · Blood Advances · 74
PDF
A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia
2016 · Ivana Gojo, Jan H. Beumer, et al. · Clinical Cancer Research · 64
Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia
2012 · J. E. Karp, E. Garrett-Mayer, et al. · Haematologica · 60
PDF
Evidence for involvement of tumor necrosis factor‐α in apoptotic death of bone marrow cells in myelodysplastic syndromes
1999 · Suneel D. Mundle, Ambereen Ali, et al. · American Journal of Hematology · 58
A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia
2016 · Keith W. Pratz, Michelle A. Rudek, et al. · Clinical Cancer Research · 44
BL‐8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open‐label safety and efficacy phase 2a study
2020 · Gautam Borthakur, Yishai Ofran, et al. · Cancer · 43
PDF
Advances in treating acute myeloid leukemia
2014 · Margaret M. Showel, Mark Levis · F1000Prime Reports · 35
PDF
Cell cycle kinetic studies in 68 patients with myelodysplastic syndromes following intravenous iodo- and/or bromodeoxyuridine.
1997 · A Raza, S Alvi, et al. · PubMed · 33
Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide
2020 · Jonathan A. Webster, Leo Luznik, et al. · Blood Advances · 31
PDF
Biological characteristics of myelodysplastic syndrome patients who demonstrated high versus no intramedullary apoptosis
1999 · Saleem Dar, Suneel Mundle, et al. · European Journal Of Haematology · 29
A 2:1 randomized, open-label, phase II study of selinexor vs. physician’s choice in older patients with relapsed or refractory acute myeloid leukemia
2021 · Kendra Sweet, Bhavana Bhatnagar, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 21
Checkpoint Inhibitor Therapy and Graft Versus Host Disease in Allogeneic Bone Marrow Transplant Recipients of Haploidentical and Matched Products with Post-Transplant Cyclophosphamide.
2016 · Laura K Schoch, Ivan Borrello, et al. · Blood · 21
Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS
2020 · Joshua F. Zeidner, Hanna A. Knaus, et al. · Leukemia · 18
Rapidly progressive cutaneous Rhizopus microsporus infection presenting as Fournier's gangrene in a patient with acute myelogenous leukemia
2011 · C.M. Durand, C.D. Alonso, et al. · Transplant Infectious Disease · 17
Tyrosine Kinase Inhibitor Induced Isolated Pericardial Effusion
2015 · Vineet Agrawal, Eric S. Christenson, et al. · Case Reports in Oncology · 16
Fibrinogen consumption and use of heparin are risk factors for delayed bleeding during acute promyelocytic leukemia induction
2019 · Bryan C. Hambley, Kelly J. Norsworthy, et al. · Leukemia Research · 12
Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature
2017 · Kelly J. Norsworthy, Amy E. DeZern, et al. · Leukemia Research · 12
Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies
2016 · Kelly J. Norsworthy, Eunpi Cho, et al. · Leukemia Research · 12
Works count: 66
Citation count: 2,008
H-index: 19
I10-index: 27
Year
Topic
Type